




GenMark Diagnostics

Superior Solutions for Multiplex Molecular Testing
& Personalized Medicine



Forward-Looking Statements

This presentation contains forward-looking statements about GenMark Diagnostics, Inc. These statements involve known and unknown risks that relate to the Company's future events or future financial performance and the actual results could differ materially from those discussed in this presentation, including Factors that may cause the Company's actual results to differ materially from those discussed in the presentation, include:

- failure to obtain sufficient funding for the continued development and commercialization of the Company's products;
- failure to expand the Company's menu of diagnostic tests, including the failure to obtain licenses to additional biomarkers on commercially reasonable terms;
- increases in the Company's projected expenditures on sales and marketing, research and development and administrative activities;
- less than anticipated growth in the market for diagnostic testing generally and for the tests the Company is developing or may develop in the future;
- failure of the Company's products to gain market acceptance domestically or internationally;
- inability to obtain regulatory clearance or approval for any of the Company's products;
- changes in the regulatory environment which may adversely impact the commercialization of the Company's new products and result in significant additional capital expenditures;
- failure to enter into or maintain successful strategic alliances, which may delay the development or commercialization of the Company's products or may result in significant additional expenditures;
- inability to attract or retain skilled personnel for the Company's product development and commercialization efforts;
- inability to protect the Company's intellectual property and operate the Company's business without infringing upon the intellectual rights of others, which could result in litigation and significant expenditures;
- refusal of third-party payors to reimburse the Company's customers for use of diagnostic systems and tests; and
- failure to develop the Company's next-generation AD-8 System with the capabilities the Company intends to offer.

Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of GenMark's Registration Statement on Form S-1. The forward-looking statements contained in this presentation represent the Company's estimates and assumptions only as of the date of this presentation and the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this presentation as a result of new information, future events or changes in the Company's expectations.



Business Evolution

1995



Original Technology
invented by Jon Faiz
Kayyem, PhD

Caltech Innovation

2000



Clinical Micro
Sensors
acquired by
Motorola

1st Generation
eSensor
Platform
Developed

2005



Osmetech plc
acquires Clinical
Micro Sensors
AIM Listed

XT8 Platform
Developed

2010



Consolidate all Ops in
San Diego
New Board and
Management
New Commercial Team
New menu-driven strategy
Nasdaq Listing

\$100M+ invested in tech/product development and IP



Large Growing Market

Multiplex Molecular Diagnostics growing ~14% CAGR

Main Growth Drivers


- Genomics discoveries
- Conversion from “LDT” to IVD
- Decentralization

Areas of high growth (est. CAGR)

- Personalized medicine (38%)
- Infectious disease panels (>14%)
- Oncology (16%)


Source: Kalorama, Frost and Sullivan, L.E.K. 2009

U.S. MDx Supplier Revenues \$ Billions



Fragmented Competition

Increasing Emphasis on Multiplex IVD MDx




Companies listed are representative
Positioning reflects management's current opinion and is subject to change



GenMark Target Customers

XT-8 System


Post-PCR –
1000 Labs



Target Customers: US only




GenMark: Simplified, Standardized, Scalable



The GenMark eSensor Technology

- Electronic DNA detection
- Highly specific and sensitive
- No washing or purification steps
- Extremely stable chemistry
- Heavily protected Intellectual Property
- Fully Developed and Commercialized



GenMark's Competitive Advantage



Superior Quality

- Fast processing – 30 minutes
- 100% accuracy in multiple IVD products
- Minimal DNA input required



Reliable

- No operator interpretation
- No calibration required
- Virtually maintenance free
- Ease of Test Development



Convenient Workflow


- Minimal sample handling
- Easy-to-use software interface
- Easily Integrated & Scalable platform

Sources: Package Inserts, LEK Market Research, Scientific Conference Posters



The Business Model

Placements + Menu = Reagent Annuity




For illustration only.


Model assumes an average annual revenue per test per instrument of \$30K.



Business Strategy



Business Strategy



FDA Cleared IVD Tests



Cystic Fibrosis Genotyping

- For couples, expecting couples, newborn screening/confirmation
- Addresses an estimated \$70M US market
- ACOG/ACMG recommended Panel



Warfarin Sensitivity

- 2 Million new patients/year in US alone
- Genetic testing recommended by FDA and PBMs
- NIH clinical outcomes study underway



Thrombophilia Risk Test (TRT)

- Factor V Leiden, Factor II Prothrombin & MTHFR
- Thrombophilia disorders affect 1 in 1000 individuals
- Only cleared test for MTHFR 1298

Source: LEK, AEI-Brookings Joint Center, Management estimates

In Development for FDA submission



Respiratory Viral Panel (RVP)

- Approx. 20 upper respiratory viruses including H1N1
- Immuno-compromised and high risk patients
- 200,000+ people hospitalized w/ respiratory infections annually



Plavix Metabolism (2C19)

- Over 1.6 million new US prescriptions annually
- Tests for gene variations on Plavix label
- Indicates reduced effectiveness in 2-14% of patients



K-ras Mutation

- Tests for mutations related to colorectal cancer treatments
- Over 200,000 US patients with related forms of cancer
- Rules out anti-EGFR therapy if mutation is present


Source: Frost and Sullivan, FDA statement, L.E.K. 2009

Future Menu Development

Test Name	Market Opportunity
Lower Respiratory Tract Infections	Community Acquired Pneumonia
Central Nervous System Infections	Meningitis and Encephalitis
Hepatitis C Virus Genotyping	Type and Subtype
2D6 Tamoxifen Metabolism	Breast Cancer
EGFR Pathway	Colorectal and Other Cancers
Human Papillomavirus Genotyping	High Risk Typing/Cervical Cancer



Business Strategy



Commercial Execution

- Target 1,000 top molecular laboratories
- Flexible placement strategies to accelerate market uptake
 - System sales, leases and reagent rental agreements
- Ten Field Sales/Support representatives expanding to twenty +
- Recruiting and training highly productive “A” players
- Marketing support with key opinion leaders, physician tools, publications and trade shows
- Establishing International distributor network




The Road to Operational Excellence


- Best in Class Quality System
- Conversion to Lean Manufacturing Operations
- Upgraded ERP system
- Highly Efficient Customer Service & Support Interface



Business Strategy





Sample to Answer Multiplexed Molecular IVD Testing




Next Gen Feasibility Completed

- Sample to Answer Capability
- Based on XT-8 system and cartridge
- Integrates Extraction and PCR
- Engineering/Systems Integration Partner Selection Process Underway



Target Customers



Target Customers: US only

Summary Statement of Operations

unaudited

(\$ in thousands)	2008	2009	Q1 2010	Q2 2010	Q3 2010	YTD 2010
Revenue	\$647	\$998	\$399	\$651	\$667	\$1,717
Gross Loss	-2,591	-3,334	-168	-212	-554	-934
Sales & Marketing	3,394	3,182	1,058	1,204	1,109	3,371
R&D	13,424	5,634	1,454	1,724	1,669	4,847
G&A	9,633	8,289	2,167	2,002	1,592	5,761
Operating Loss	-29,041	-20,438	-4,847	-5,142	-4,924	-14,913
Net Loss	-28,363	-19,963	-4,849	-5,137	-4,917	-14,903
Operating cash use	(\$26,169)	(\$15,444)	(\$4,982)	(\$4,127)	(\$4,481)	(\$13,590)




Summary Balance Sheet

unaudited


(\$ in thousands)	September 30, 2010
Cash	\$24,144
AR & Inventory	1,273
Other assets	491
PPE, Intangibles, other	2,461
Total Assets	28,369
AP & Accrued Comp	2,481
Other liabilities	1,768
Stockholders Equity	24,120
Liabilities & Equity	28,369




Installed Base Steadily Growing



Reagent Revenue Increasing



Accelerating Annuity per System



Investment Highlights

- Expanding \$2+ billion Market, High Growth Multiplex Segment
- Management Team and Board with proven record
- Attractive Reagent Annuity Business Model Driven by High Value, Clinically Relevant, IVD Molecular Tests
- Fully Developed, Simple to Use FDA-cleared Platform
- Deep pipeline of products in development for FDA submission
- Extensive IP portfolio with 94 patents approved in the US



GenMark Diagnostics

Superior Solutions for Multiplex Molecular Testing
& Personalized Medicine

